JNJ-5322 Improves Efficacy, Oral Toxicity in Multiple Myeloma

As a caregiver, I'm on the lookout for myeloma research news

The word “caregiver” usually conjures up images of hands-on support: providing comfort, helping out with everyday tasks, and managing medications. However, for those of us navigating the complex world of illnesses like myeloma, a major aspect of the role unfolds quietly, usually in the dead of night, when we are seated in front of a glowing screen. It is the silent vigil, the unrelenting search for information that could possibly be the breakthr…

JNJ-5322 Improves Efficacy, Oral Toxicity in Multiple Myeloma

The trispecific antibody JNJ-5322 demonstrated superior efficacy vs approved agents in multiple myeloma in results shared at the 2025 EHA Congress.